tiprankstipranks
Seelos Therapeutics (DE:NXEN)
FRANKFURT:NXEN

Seelos Therapeutics (NXEN) Cash flow

0 Followers

Seelos Therapeutics Cash Flow

DE:NXEN's free cash flow for Q2 2023 was $-5.90M. For the 2023 fiscal year, DE:NXEN's free cash flow was decreased by $-12.61M and operating cash flow was $-5.90M. See a summary of the company’s cash flow.
Cash Flow
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Operating Cash Flow
$ -40.42M$ -61.60M$ -48.99M$ -20.91M$ -19.30M$ -8.13M
Investing Cash Flow
--$ 5.64M--$ 0.00
Financing Cash Flow
$ 5.01M$ -1.60M$ 112.07M$ 26.31M$ 29.52M$ 5.38M
Cash Flow From Discontinued Operation
------
Other Cash Adjustment Inside Changein Cash
------
End Cash Position
$ 73.51M$ 15.53M$ 78.73M$ 15.66M$ 10.26M$ 3.58M
Income Tax Paid Supplemental Data
---$ 0.00$ 0.00$ 0.00
Interest Paid Supplemental Data
$ 273.00K$ 11.00K$ 10.00K$ 11.00K$ 16.00K$ 0.00
Issuance Of Capital Stock
$ 1.04M$ 556.00K$ 98.06M$ 26.12M$ 25.01M$ 4.79M
Issuance Of Debt
$ -5.49M$ -1.89M$ -13.55M$ 147.00K$ 0.00-
Repayment Of Debt
$ -5.49M$ -1.89M$ -13.55M$ 0.00-$ 0.00
Free Cash Flow
$ -40.42M$ -61.60M$ -48.99M$ -20.91M$ -19.30M$ -8.13M
Domestic Sales
------
Foreign Sales
------
Currency in USD

Seelos Therapeutics Cash Flow

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis